Early appropriate therapy of Gram-positive bloodstream infections: the conservative use of new drugs
Introduction
Infections caused by multidrug-resistant microorganisms present daily challenges to infectious diseases physicians and their patients. Bacteria are champions of evolution, and several have adapted to a point where they pose a serious clinical challenge for humans. These bacteria have recently been described as the ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp., to emphasize that they currently cause most hospital infections and effectively escape the effects of antibacterial drugs [1]. It is difficult to imagine undertaking today's surgical procedures, transplantations, cancer chemotherapy or the care of critically ill or HIV-infected patients without effective antimicrobial agents.
Despite the increasing importance of Gram-positive bacterial infections [2, 3], and in particular the clinical problems related to meticillin-resistant S. aureus (MRSA) bacteraemia [4, 5, 6], there is no international consensus on the diagnosis and management of Gram-positive bloodstream infections (BSI). In a recent survey of >24 000 cases of nosocomial bacteraemia in 47 US hospitals, Gram-positive pathogens were responsible for 65% of infections, the most common organisms being coagulase-negative staphylococci (CoNS), S. aureus and enterococci [7]. In the present paper the focus is restricted to the treatment of infections caused by S. aureus.
Despite its sustained in vitro microbiological inhibitory activity, clinicians now question the continued utility of vancomycin for MRSA infections [8, 9]. Within the past 5 years, multiple reports have described MRSA strains with vancomycin minimum inhibitory concentrations (MIC) at the high end of the Clinical and Laboratory Standards Institute (CLSI) susceptibility range (2 mg/L) [8, 10]. Although data suggest that vancomycin has reduced activity against MRSA infections when MICs are at the high end of the susceptibility range [11, 12, 13, 14, 15], it is important to realize the important limitations of the clinical laboratory in detecting reduced susceptibility and resistance to vancomycin [16].
Furthermore, vancomycin's limitations as an antibacterial agent include slow bactericidal activity and relatively poor tissue penetration. Inadequate dosing may, however, contribute to vancomycin's poor performance; the standard recommendation for trough concentrations of 5–10 mg/L is inadequate for serious infections such as bacteraemia and endocarditis. Trough levels of 15–20 mg/L are probably necessary; however they are often associated with increased nephrotoxicity [17, 18].
Treatment guidelines for bacteraemia are primarily based on specific sites of associated infections, such as infective endocarditis (IE) [19, 20, 21, 22] and catheter-related infections [23]. The selection of antimicrobial agents for S. aureus bacteraemia is typically made on the basis of a combination of antibiotic susceptibility, local formulary restrictions, clinical experience and often less-than-rigorous clinical trial data. Although no clinical trials suggest the superiority of vancomycin over any comparator, some have provided evidence of its inferiority. Consideration should therefore be given to the use of alternative agents in the treatment of serious S. aureus infections [24].
Section snippets
New drugs
Despite the recent dramatic reduction in antibiotic research by pharmaceutical companies, several compounds have been developed to treat Gram-positive infections, including quinupristin– dalfopristin, linezolid, daptomycin and tigecycline. Although these agents are extremely valuable in the fight against MRSA, each has limitations. New lipoglycopeptides (telavancin, dalbavancin and oritavancin) are in an advanced phase of clinical development. Similarly, new broad-spectrum cephalosporins active
Discussion
The treatment of serious drug-resistant Gram-positive infections remains a challenge, despite the development of several new antibiotics over the past 10 years. Vancomycin, still the most frequently chosen antibiotic for the treatment of severe MRSA infections, has become a suboptimal therapy in selected clinical settings. However, clinical trials have consistently failed to demonstrate superiority for the new antibiotics, despite promising antimicrobial profiles, and clinicians have begun
References (49)
- et al.
Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia
Diagn Microbiol Infect Dis
(2005) - et al.
Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis
Clin Ther
(2006) - et al.
Laboratory tools and strategies for methicillin-resistant Staphylococcus aureus screening, surveillance and typing: state of the art and unmet needs
Clin Microbiol Infect
(2009) - et al.
Management of methicillin resistant Staphylococcus aureus infections
Clin Microbiol Infect
(2009) - et al.
In vitro activity of tigecycline (GAR-936) tested against 11 859 recent clinical isolates associated with community acquired respiratory tract and Gram-positive cutaneous infections
Diagn Microbiol Infect Dis
(2004) Glycylcyclines: third generation tetracycline antibiotics
Curr Opin Pharmacol
(2001)- et al.
Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides
Biochim Biophys Acta
(2006) The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria
Clin Microbiol Infect
(2006)- et al.
Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus
Diagn Microbiol Infect Dis
(2008) - et al.
Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity
Heart Lung
(2006)
Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin
Heart Lung
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
Clin Infect Dis
Overview of nosocomial infections caused by gram negative bacilli
Clin Infect Dis
Major trends in the microbial etiology of nosocomial infection
Am J Med
The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges
Infect Control Hosp Epidemiol
Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia
Infect Control Hosp Epidemiol
Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study
Clin Infect Dis
Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy
Clin Infect Dis
The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus
Clin Infect Dis
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05
J Antimicrob Chemother
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity
Arch Intern Med
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy
Clin Infect Dis
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia
J Clin Microbiol
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia
Clin Infect Dis
Cited by (9)
Evaluation of the treatment of methicillin-resistant staphylococcus aureus bacteremia
2015, American Journal of the Medical SciencesAntimicrobial susceptibility of streptococcus sp. to quinupristin- dalfopristin in China
2014, Biomedical and Environmental SciencesCharacterization of antimicrobial resistance and virulence genes in Enterococcus spp. isolated from retail meats in Alberta, Canada
2012, International Journal of Food MicrobiologyCitation Excerpt :In the present study all enterococci were susceptible to CIP, VAN, LZD and DAP, antimicrobials of great importance in human medicine. Fifteen E. faecalis isolates were resistant to the tigecycline, an antibiotic recommended for use in humans in the United States (Grossi, 2009; Gales et al., 2008). Tigecycline is a glycylcycline antibiotic with effectiveness against multidrug resistant Enterococcus spp.
MRSA in Croatia: Prevalence and management
2016, Expert Review of Anti-Infective TherapyTherapy of intracellular Staphylococcus aureus by tigecyclin
2013, BMC Infectious DiseasesAntistaphylococcal activity of novel salicylanilide derivatives
2012, Current Drug Discovery Technologies